Barclays Cuts Moderna (NASDAQ:MRNA) Price Target to $25.00

Moderna (NASDAQ:MRNA) had its target price lowered by Barclays from $31.00 to $25.00 in a report published on Friday morning,Benzinga reports. The brokerage currently has an equal weight rating on the stock.

MRNA has been the topic of a number of other reports. Morgan Stanley boosted their price target on Moderna from $31.00 to $32.00 and gave the stock an “equal weight” rating in a report on Friday, October 10th. Citigroup reduced their price target on shares of Moderna from $30.00 to $28.00 and set a “neutral” rating on the stock in a report on Thursday, October 23rd. Leerink Partners dropped their price objective on shares of Moderna from $18.00 to $15.00 and set an “underperform” rating for the company in a report on Friday, August 22nd. Evercore ISI set a $32.00 target price on Moderna in a research report on Friday, August 1st. Finally, Wells Fargo & Company reissued an “equal weight” rating on shares of Moderna in a research note on Sunday, July 13th. One equities research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, twelve have issued a Hold rating and five have assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $36.14.

Moderna Stock Up 0.9%

NASDAQ:MRNA traded up $0.22 on Friday, hitting $24.76. The stock had a trading volume of 8,217,007 shares, compared to its average volume of 10,965,282. Moderna has a 52-week low of $23.04 and a 52-week high of $48.92. The stock has a market cap of $9.67 billion, a price-to-earnings ratio of -3.07 and a beta of 2.02. The business’s 50-day simple moving average is $25.81 and its two-hundred day simple moving average is $27.14.

Moderna (NASDAQ:MRNA) last released its quarterly earnings results on Thursday, November 6th. The company reported ($0.51) earnings per share for the quarter, topping the consensus estimate of ($2.15) by $1.64. The business had revenue of $1.02 billion for the quarter, compared to the consensus estimate of $893.29 million. Moderna had a negative net margin of 139.61% and a negative return on equity of 29.81%. The company’s quarterly revenue was down 45.4% on a year-over-year basis. During the same period last year, the firm earned $0.03 earnings per share. Moderna has set its FY 2025 guidance at EPS. As a group, equities research analysts anticipate that Moderna will post -9.61 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in MRNA. S Bank Fund Management Ltd bought a new stake in shares of Moderna during the first quarter valued at approximately $25,000. Rothschild Investment LLC increased its holdings in Moderna by 94.1% during the 2nd quarter. Rothschild Investment LLC now owns 920 shares of the company’s stock worth $25,000 after purchasing an additional 446 shares during the period. TD Private Client Wealth LLC increased its holdings in Moderna by 348.8% during the 2nd quarter. TD Private Client Wealth LLC now owns 956 shares of the company’s stock worth $26,000 after purchasing an additional 743 shares during the period. Atlantic Union Bankshares Corp bought a new stake in Moderna during the 2nd quarter valued at $26,000. Finally, SVB Wealth LLC purchased a new stake in shares of Moderna in the 1st quarter worth $28,000. 75.33% of the stock is currently owned by institutional investors.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.